Drug intelligence / Profile preview

Oakp-11

Development stage: Preclinical
Lead developer: Akaal Pharma
Modality: Small Molecules
Administration: Oral, Topical

Overview

Oakp-11 is a potent and selective small molecule modulator of the Sphingosine-1-phosphate receptor 1 (S1P1) developed by Akaal Pharma. It is being investigated for the treatment of various autoimmune and inflammatory conditions, including neuropathic pain, acne vulgaris, alopecia areata, and atopic dermatitis. The drug is designed to offer a differentiated clinical profile with high receptor selectivity and an improved safety margin, specifically aiming to minimize the cardiovascular side effects and profound lymphopenia often associated with other S1P receptor modulators. Oakp-11 is developed for both oral and topical administration.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on Oakp-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oakp-11.

Explore the full profile